Vogenx, Inc.

What they do

Vogenx is a clinical-stage life science and drug development company focused on novel therapeutics for serious diseases associated with human metabolism dysfunction, including post-bariatric hypoglycemia (PBH) and gastroparesis. Its lead investigational product candidate is mizagliflozin, a selective SGLT1 inhibitor in development for disorders related to glucose absorption and postprandial dysregulation. The company is also developing VGX-2857 for weight maintenance. Operations to date have been limited to organizing and staffing, business planning, raising capital, and conducting research and development, including nonclinical and clinical testing of mizagliflozin.

Revenue drivers

• Product sales — Vogenx has no products approved for commercial sale and has not generated any revenue from product sales. Any future revenue would depend on successful clinical development and regulatory approval of its product candidates, which has not occurred.

Recent performance

For the three months ended June 30, 2026, Vogenx reported a net loss of approximately $384 thousand, compared to a net loss of approximately $295 thousand for the three months ended June 30, 2025. For the six months ended June 30, 2026, the net loss was approximately $860 thousand, compared to approximately $651 thousand for the six months ended June 30, 2025. As of June 30, 2026, the company had total assets of $1.4 million, total liabilities of $3.2 million, and shareholders' equity of negative $1.8 million. Cash and cash equivalents were $193,017 as of June 30, 2026. The company had an accumulated deficit of approximately $11.7 million as of June 30, 2026.

Strategy

Vogenx's primary objective is to advance mizagliflozin through clinical development and towards regulatory approval for PBH, gastroparesis, and GIP-dependent Cushing's Syndrome. The company also plans to advance VGX-2857 for weight maintenance. It expects expenses and operating losses to increase substantially as it advances research and development, seeks regulatory approval, establishes manufacturing capabilities, and prepares for potential commercialization. Historically, operations have been funded primarily through sales of Series A convertible preferred stock and convertible promissory notes, which generated approximately $11.5 million in aggregate gross proceeds. The company may also in-license or acquire additional product candidates and establish collaborations.

Risks

• No product revenue and significant operating losses — Vogenx has no approved products and has incurred net losses since inception, with an accumulated deficit of approximately $11.7 million as of June 30, 2026, and expects substantial increases in expenses and losses.
• Going concern and liquidity risk — With cash and cash equivalents of only $193,017 as of June 30, 2026, and total liabilities exceeding total assets, the company may need to raise additional capital to fund operations.
• Clinical development and regulatory risk — The company's product candidates, including mizagliflozin and VGX-2857, are in clinical development and have not received regulatory approval; they may fail in trials or fail to obtain approval.
• Dependence on key product candidates — Vogenx's future success depends heavily on the successful development and eventual commercialization of mizagliflozin and VGX-2857, and any delay or failure would materially harm the company.

Outlook

Management anticipates that expenses and operating losses will increase substantially for the foreseeable future as the company advances its pipeline, including mizagliflozin for PBH, gastroparesis, and GIP-dependent Cushing's Syndrome, and VGX-2857 for weight maintenance. Vogenx will not generate revenue from product sales unless and until it successfully completes clinical development and obtains regulatory approval for one or more product candidates. The company expects to incur additional costs as a public company and may need to raise additional capital to fund its operations.